organization · Reporting owner
Decheng Capital China Life Sciences USD Fund III, L.P.
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALPINE IMMUNE SCIENCES, INC.
Report date May 18, 2024 · Filed May 21, 2024
Jointly reported with Cui Xiangmin, Decheng Capital Management III (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-05-18 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-05-18 · Other · Disposed 6,582,380 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F3: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-05-18 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-05-18 · Other · Disposed 1,735,544 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding. F4: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2029-01-17 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.62 · Expires 2030-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.45 · Expires 2031-01-03 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-05-20 · Disposition to issuer · Disposed 7,650 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.89 · Expires 2032-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2033-01-02 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.00 · Expires 2034-01-01 | Direct | 0 |
Reported balance
After 2024-05-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-05-20 · Disposition to issuer · Disposed 17,500 · Balance 0 F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option. F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof. F9: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: (Continued from Footnote 1) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding.
F3: These securities are owned directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Xiangmin Cui is the manager of Decheng Capital Management III (Cayman), LLC, the general partner of Fund III. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F4: These securities are owned directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Decheng Capital Global Healthcare GP, LLC, the general partner of Healthcare. Dr. Cui disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein.
F5: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
F6: The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable.
F7: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option.
F8: (Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof.
F9: 1/12th of the shares subject to the option become vested and exercisable on February 2, 2024 and 1/12 of the shares subject to the option shall vest monthly thereafter.
BeyondSpring Inc.
Report date October 16, 2025 · Filed October 21, 2025
Jointly reported with Decheng Capital Management III (Cayman), LLC, Decheng Capital China Life Sciences USD Fund II, L.P., Decheng Capital Management II (Cayman), LLC, Decheng Capital Global Healthcare Fund (Master), LP, Decheng Capital Global Healthcare GP, LLC, Cui Xiangmin
Section 16 reporting ended · disclosed 2025-10-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund III, L.P. | 1,518,893 |
Last balance in matching sequence
After 2025-10-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2025-10-16 · Sale · Disposed 85,798 · Balance 1,564,406 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Row 2 · 2025-10-17 · Sale · Disposed 45,513 · Balance 1,518,893 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital China Life Sciences USD Fund II, L.P. | 1,617,409 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,617,409 F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy Decheng Capital Global Healthcare Fund (Master), LP | 891,734 |
Reported balance
Holding disclosure · report date 2025-10-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 891,734 F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These securities are held directly by Decheng Capital China Life Sciences USD Fund II, L.P. ("Fund II"). Decheng Capital Management II (Cayman), LLC ("GP II") is the general partner of Fund II. Dr. Cui is the manager of GP II. Each of Fund II, GP II and Dr. Cui may be deemed to beneficially own the securities held by Fund II. Each of GP II and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F5: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
Cue Health Inc.
Report date September 28, 2021 · Filed September 30, 2021
Jointly reported with Decheng Capital Management III (Cayman), LLC
Section 16 reporting ended · disclosed 2021-09-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,192,468 |
Reported balance
After 2021-09-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-09-28 · Conversion · Acquired 8,192,468 · Balance 8,192,468 F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-09-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-09-28 · Conversion · Disposed 8,192,468 · Balance 0 F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2: The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2025 Filed Oct 21, 2025 00:00 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 45,513 | $1.76 | $80,102.88 |
DisclosureSEC source: 0001231919-25-000335 · form4-10202025_111053.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,518,893 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 16, 2025 Filed Oct 21, 2025 00:00 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 85,798 | $1.72 | $147,572.56 |
DisclosureSEC source: 0001231919-25-000335 · form4-10202025_111053.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,564,406 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.795 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 15, 2025 Filed Oct 16, 2025 00:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 17,960 | $1.65 | $29,634.00 |
DisclosureSEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,650,204 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.60 to $1.685 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 00:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 28,495 | $1.65 | $47,016.75 |
DisclosureSEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,668,164 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.62 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 13, 2025 Filed Oct 16, 2025 00:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 107,361 | $1.70 | $182,513.70 |
DisclosureSEC source: 0001231919-25-000323 · form4-10162025_121006.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,696,659 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 10, 2025 Filed Oct 10, 2025 21:58 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,390 | $1.77 | $4,230.30 |
DisclosureSEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,804,020 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 21:58 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,979 | $1.81 | $7,201.99 |
DisclosureSEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,806,410 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 21:58 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 7,507 | $1.77 | $13,287.39 |
DisclosureSEC source: 0001231919-25-000308 · form4-10102025_091053.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,810,389 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.805 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 07, 2025 Filed Oct 7, 2025 22:14 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,100 | $1.79 | $3,759.00 |
DisclosureSEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,817,896 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 22:14 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 17,500 | $1.78 | $31,150.00 |
DisclosureSEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,819,996 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.7879 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 22:14 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 600 | $1.76 | $1,056.00 |
DisclosureSEC source: 0001231919-25-000292 · form4-10072025_101049.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,837,496 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.79 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 00:51 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 600 | $1.73 | $1,038.00 |
DisclosureSEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,838,096 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 00:51 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,601 | $1.80 | $4,681.80 |
DisclosureSEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,838,696 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.785 to $1.81 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 30, 2025 Filed Oct 3, 2025 00:51 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 4,464 | $1.81 | $8,079.84 |
DisclosureSEC source: 0001231919-25-000278 · form4-10032025_121037.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Management II (Cayman), LLC · CIK 0002089149 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,841,297 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 00:06 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 500 | $1.75 | $875.00 |
DisclosureSEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,845,761 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 26, 2025 Filed Sep 30, 2025 00:06 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 600 | $1.68 | $1,008.00 |
DisclosureSEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,846,261 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 25, 2025 Filed Sep 30, 2025 00:06 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 700 | $1.66 | $1,162.00 |
DisclosureSEC source: 0001231919-25-000258 · form4-09302025_120929.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,846,861 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.64 to $1.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 24, 2025 Filed Sep 24, 2025 22:49 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,256 | $1.68 | $3,790.08 |
DisclosureSEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,847,561 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 23, 2025 Filed Sep 24, 2025 22:49 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 4,106 | $1.72 | $7,062.32 |
DisclosureSEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,849,817 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.65 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 22:49 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 5,410 | $1.83 | $9,900.30 |
DisclosureSEC source: 0001231919-25-000244 · form4-09242025_100902.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,853,923 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 19, 2025 Filed Sep 19, 2025 22:03 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,656 | $1.79 | $6,544.24 |
DisclosureSEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,859,333 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 18, 2025 Filed Sep 19, 2025 22:03 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 5,307 | $1.74 | $9,234.18 |
DisclosureSEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,862,989 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 22:03 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,304 | $1.83 | $4,216.32 |
DisclosureSEC source: 0001231919-25-000221 · form4-09192025_100903.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,868,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.80 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 23:45 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 840 | $1.88 | $1,579.20 |
DisclosureSEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,870,600 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.86 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 23:45 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,570 | $1.84 | $4,728.80 |
DisclosureSEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,871,440 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 12, 2025 Filed Sep 16, 2025 23:45 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 700 | $1.85 | $1,295.00 |
DisclosureSEC source: 0001736814-25-000007 · form4-09162025_110941.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,874,010 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.83 to $1.87 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 23:43 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,820 | $1.90 | $7,258.00 |
DisclosureSEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,874,710 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.94 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 10, 2025 Filed Sep 11, 2025 23:43 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 8,176 | $1.93 | $15,779.68 |
DisclosureSEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,878,530 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 09, 2025 Filed Sep 11, 2025 23:43 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 9,050 | $1.97 | $17,828.50 |
DisclosureSEC source: 0001415889-25-024317 · form4-09112025_110935.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,886,706 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 08, 2025 Filed Sep 8, 2025 22:55 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 7,090 | $1.93 | $13,683.70 |
DisclosureSEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,895,756 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 22:55 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 1,106 | $1.86 | $2,057.16 |
DisclosureSEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,902,846 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.82 to $1.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 22:55 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 803 | $1.82 | $1,461.46 |
DisclosureSEC source: 0001415889-25-023907 · form4-09082025_100931.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,903,952 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 03, 2025 Filed Sep 3, 2025 23:57 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 1,270 | $1.81 | $2,298.70 |
DisclosureSEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,904,755 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 23:57 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,800 | $1.78 | $4,984.00 |
DisclosureSEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,906,025 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.67 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 29, 2025 Filed Sep 3, 2025 23:57 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 800 | $1.74 | $1,392.00 |
DisclosureSEC source: 0001415889-25-023607 · form4-09032025_110901.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,908,825 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 28, 2025 Filed Aug 29, 2025 00:39 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 809 | $1.81 | $1,464.29 |
DisclosureSEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,909,625 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 27, 2025 Filed Aug 29, 2025 00:39 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 1,300 | $1.78 | $2,314.00 |
DisclosureSEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,910,434 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 26, 2025 Filed Aug 29, 2025 00:39 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,000 | $1.79 | $3,580.00 |
DisclosureSEC source: 0001415889-25-023258 · form4-08292025_120807.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,911,734 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 25, 2025 Filed Aug 25, 2025 23:46 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 300 | $1.77 | $531.00 |
DisclosureSEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,913,734 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 22, 2025 Filed Aug 25, 2025 23:46 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,376 | $1.75 | $4,158.00 |
DisclosureSEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,914,034 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.77 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 23:46 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,034 | $1.79 | $5,430.86 |
DisclosureSEC source: 0001415889-25-022967 · form4-08252025_110849.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,916,410 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.74 to $1.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 22:35 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,456 | $1.74 | $6,013.44 |
DisclosureSEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 3 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,919,444 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.72 to $1.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 22:35 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 3,604 | $1.77 | $6,379.08 |
DisclosureSEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,922,900 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.75 to $1.85 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 22:35 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 47,668 | $2.03 | $96,766.04 |
DisclosureSEC source: 0001415889-25-022532 · form4-08202025_100823.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,926,504 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 15, 2025 Filed Aug 15, 2025 23:11 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,900 | $2.00 | $5,800.00 |
DisclosureSEC source: 0001415889-25-022119 · form4-08152025_110853.xml · nonDerivative · entry 2 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,974,172 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 14, 2025 Filed Aug 15, 2025 23:11 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,000 | $2.00 | $4,000.00 |
DisclosureSEC source: 0001415889-25-022119 · form4-08152025_110853.xml · nonDerivative · entry 1 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital China Life Sciences USD Fund III, L.P. Disclosed balance after: 1,977,072 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.00 to $2.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares vat each separate price within the range set forth in this footnote. F2 · ownership.nature: These securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Dr. Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. Each of GP III and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| August 04, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 2,196 | $2.18 | $4,787.28 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 17 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 891,734 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 18, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 900 | $2.20 | $1,980.00 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 16 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 893,930 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 17, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 20,572 | $2.19 | $45,052.68 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 15 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 894,830 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
| July 16, 2025 Filed Aug 11, 2025 21:07 UTC | BeyondSpring Inc. BYSI · Entity 7539 | SaleOrdinary Shares | 5,396 | $2.24 | $12,087.04 |
DisclosureSEC source: 0001415889-25-021441 · form4-08112025_090812.xml · nonDerivative · entry 14 Decheng Capital China Life Sciences USD Fund III, L.P. · CIK 0001736814 · 10% owner Decheng Capital Management III (Cayman), LLC · CIK 0001747821 · 10% owner Decheng Capital China Life Sciences USD Fund II, L.P. · CIK 0001650291 · 10% owner Decheng Capital Global Healthcare Fund (Master), LP · CIK 0001949026 · 10% owner Decheng Capital Global Healthcare GP, LLC · CIK 0001949027 · 10% owner Cui Xiangmin · CIK 0001487815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Decheng Capital Global Healthcare Fund (Master), LP Disclosed balance after: 915,402 F1 · ownership.nature: These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Dr. Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.